European Journal of Heart Failure publishes new randomized controlled clinical study of RESPeRATE

...Lod Israel. September 27th 2011 InterCure Ltd. a medical device co...Chronic heart failure (CHF) affects about 5 million patients in the U.... The study was conducted by Inger Ekman MD Professor of Medicine In... CHF is disabling and leads to decreased quality of life frequent hos...

Lod, Israel. September 27th, 2011 InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), today announced that European Journal of Heart Failure, a peer reviewed medical journal of the European Society of Cardiology, published the results of a 72-patients, randomized, controlled study which demonstrated that deviceguided respiratory modulation with RESPeRATE applied at the home setting can significantly relieve symptoms of heart failure in elderly patients.

Chronic heart failure (CHF) affects about 5 million patients in the U.S. alone. It is the most widespread cause of hospitalization of patients over 65, with over 1 million hospitalizations every year. The total cost of treating the disease is estimated at $33 billion annually. About 91% of CHF sufferers have a medical history involving hypertension.

The study was conducted by Inger Ekman, MD, Professor of Medicine, Institute of Health and Care Sciences, the Sahlgrenska Academy, University of Gothenburg, Sweden with funding from the Swedish Heart Lung Foundation. It was found that after 4 weeks of twice daily 20 minute at-home treatment sessions with RESPeRATE, patients, who modified the breathing as directed by the device , demonstrated a reduction in the severity of CHF measured by New York Heart Association (NYHA) classification, and in dyspnea (shortness of breath) that is the major reason for seeking care in the CHF population. The observed reduction was significant by both its absolute mean and in comparison with control group and/or with patients, who didn't modify breathing as directed by the device.

"CHF is disabling and leads to decreased quality of life, frequent hospitalizations and poor survival. The patient's subjective response to the condition is associated with symptoms that reflect physical aspects as well as integrated aspects of lifestyle, anxiety, depression, and expectations of the patient. The device-guided respiratory modulation provided by the RESPeRATE might have the potential to relieve symptoms of heart failure in outpatients by changing their Device-guided respiratory modulation have the potential to relieve symptoms of heart failure in outpatients by changing their breathing pattern" said Prof. Ekman.

Results are consistent with those published last year in Circulation Heart Failure by Gianfranco Parati, Professor of Medicine from St. Luca Hospital, in Milano and his colleagues. That randomized controlled study with similar use of RESPeRATE at home over 8 weeks is feasible in patients with heart failure and systolic dysfunction and demonstrated significant improvement in clinically relevant parameters for, including CHF severity; left ventricular ejection fraction and pulmonary pressure and function.

"The positive effect of the RESPeRATE on CHF patients reported by these independent studies expand the growing body of scientific evidence that already has proven RESPeRATE as a clinically valid treatment for hypertension," said Erez Gavish, President and CEO of InterCure. "We plan to continue exploring the potential of RESPeRATE and our patented device-guided respiratory modulation technology to benefit patients with other cardiovascular diseases."

RESPeRATE is the only FDA-cleared, CE-marked device indicated for the adjunctive treatment of hypertension. RESPeRATE's clinical efficacy in lowering blood pressure has been validated in 10 separate published studies and 200,000 units have been sold to consumers. RESPeRATE has not been cleared for use in the treatment of heart failure in the United States, European Union or elsewhere.

(Date:10/13/2017)... ... , ... As health professionals work to improve their approach to healthcare, there ... more than filling out a survey; in many cases health professionals and patients are ... care and research on the importance of active engagement with patients and members of ...

(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...

(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the ... save lost souls in the Philippines. “The Journey: From the Mountains to the Mission ... of the Bible. She has taught all ages and currently teaches a class of ...

(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...